Multiple securities class action lawsuits have been filed against DENTSPLY SIRONA Inc. (NASDAQ: XRAY), alleging the company made false and misleading statements regarding its Byte direct-to-consumer aligner product. The complaints cover the period from May 6, 2021, to November 6, 2024.
The lawsuits claim DENTSPLY targeted vulnerable low-income individuals for Byte aligners, even when these patients had underlying dental issues that made them ineligible for treatment. According to the allegations, the company's push for growth and sales commissions led employees to sell to contraindicated patients, potentially endangering their health.
Additionally, the legal actions assert that DENTSPLY was aware of numerous patient injuries related to Byte aligners but failed to adequately investigate or report these incidents to the U.S. Food and Drug Administration (FDA) as required. The company allegedly lacked proper systems to report injuries within the mandated 30-day timeframe.
The lawsuits also allege that DENTSPLY materially overstated the goodwill value of Byte and that its positive statements about business operations were false or misleading. Investors who purchased DENTSPLY common stock during the class period may be affected. The lead plaintiff deadline is January 27, 2025.
The law firm Kessler Topaz Meltzer & Check, LLP is involved and encourages investors with significant losses to contact them for information about legal rights.
This case highlights the importance of corporate transparency and regulatory compliance in the medical device industry, particularly regarding patient safety and FDA reporting. It may lead to increased scrutiny of direct-to-consumer orthodontic products and marketing practices, as well as prompt reevaluation of patient screening processes.
Investors in healthcare and medical device sectors should monitor developments, as the outcome could impact DENTSPLY's financial standing and reputation, and set precedents for similar cases.
